• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SERA

    Sera Prognostics Inc.

    Subscribe to $SERA
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: seraprognostics.com

    Recent Analyst Ratings for Sera Prognostics Inc.

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    See more ratings

    Sera Prognostics Inc. SEC Filings

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Sera Prognostics Inc.

      10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/7/25 4:12:05 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/7/25 4:09:55 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Sera Prognostics Inc.

      DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      4/23/25 4:14:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Sera Prognostics Inc.

      DEF 14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      4/23/25 4:10:42 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Sera Prognostics Inc.

      S-8 - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      3/19/25 4:19:27 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 10-K filed by Sera Prognostics Inc.

      10-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      3/19/25 4:16:17 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      3/19/25 4:13:49 PM ET
      $SERA
      Medical Specialities
      Health Care

    Sera Prognostics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care
    • General Counsel Jackson Benjamin sold $17,285 worth of shares (7,084 units at $2.44), decreasing direct ownership by 5% to 131,460 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:37 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Information Officer Harrison Robert Gardner sold $15,984 worth of shares (6,551 units at $2.44), decreasing direct ownership by 5% to 115,206 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:21 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Scientific Officer Boniface John J. sold $12,522 worth of shares (5,132 units at $2.44), decreasing direct ownership by 3% to 165,718 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:02 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Financial Officer Aerts Austin sold $15,553 worth of shares (6,374 units at $2.44), decreasing direct ownership by 2% to 303,328 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:16:39 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Director Mirza Mansoor Raza sold $358 worth of shares (107 units at $3.35), decreasing direct ownership by 0.24% to 43,778 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      4/8/25 5:21:24 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Director Elliott Jeffrey Thomas was granted 30,534 shares (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      3/21/25 5:18:22 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Elliott Jeffrey Thomas

      3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      3/21/25 5:16:43 PM ET
      $SERA
      Medical Specialities
      Health Care

    Sera Prognostics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care
    • William Blair initiated coverage on Sera Prognostics

      William Blair initiated coverage of Sera Prognostics with a rating of Outperform

      8/9/21 9:51:33 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen initiated coverage on Sera Prognostics

      Cowen initiated coverage of Sera Prognostics with a rating of Outperform

      8/9/21 6:30:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Citigroup initiated coverage on Sera Prognostics with a new price target

      Citigroup initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $18.00

      8/9/21 6:27:56 AM ET
      $SERA
      Medical Specialities
      Health Care

    Sera Prognostics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Sera Prognostics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

      SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      3/11/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

      SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. A live webcast of the company's presentation

      2/21/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Pricing of $50 Million Public Offering

      SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (NASDAQ:SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common

      2/10/25 10:41:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Proposed Public Offering

      SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (NASDAQ:SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock.  In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common

      2/10/25 4:01:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics to Host Virtual R&D Day on January 31

      Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts. During the event, Sera's man

      1/27/25 5:02:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      2/13/24 5:00:07 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      1/19/24 6:09:55 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      1/10/24 4:58:08 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      1/3/24 8:50:06 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      2/10/23 1:00:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      1/9/23 6:47:30 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      7/19/22 5:14:17 PM ET
      $SERA
      Medical Specialities
      Health Care

    Sera Prognostics Inc. Financials

    Live finance-specific insights

    See more
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

      SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      3/11/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics to Host Virtual R&D Day on January 31

      Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts. During the event, Sera's man

      1/27/25 5:02:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection wit

      11/6/24 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024

      SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      10/28/24 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics, with coverage on front page of publication.Data analysis fo

      8/7/24 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

      SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      7/25/24 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024. Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication.Shipped first ambient whole blood collection kits, which we believe is critical to facilitating new commercial opportunities and is expected to yield s

      5/8/24 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    Sera Prognostics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

      - Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors. "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognos

      4/12/22 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board

      SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Sandra A. J. Lawrence has joined the Sera Board of Directors. "We are very excited to have Sandra Lawrence join the Sera board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics. "Sandra brings to Sera her broad and profound leadership experience having served on multiple public and private boards across

      11/30/21 8:00:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board

      SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Zhenya Lindgardt has joined the Sera Board of Directors. "We are thrilled to have Zhenya Lindgardt bring her vast and highly relevant experience to our board to improve the well-being of mothers and babies," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics, Inc.  "Zhenya possesses the rare combination of d

      11/8/21 4:21:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs

      SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs. Dr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company's efforts to help address the healthcare disparities that disproportionately affect underserved communiti

      11/4/21 8:00:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer

      Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Dr. Paul Kearney to the position of Chief Data Officer, effective October 1, 2021. As the chief data/analytics officer, Dr. Kearney will have responsibility to help direct, manage and analyze the large and growing data sets of Sera, both scientific and busin

      9/28/21 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer

      SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company™. He joins a group of talented clinical operations and medical professionals who support Sera's collaborations with research teams across the globe. "We are honored to have Dr. Foley bring his extensive Materna

      9/15/21 8:00:00 AM ET
      $SERA
      Medical Specialities
      Health Care